AVIR — Atea Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1593899 ·
Last close
$3.96
Market Cap
$318.00M
52W High
$6.45
52W Low
$2.92
ADV30
305,782
Next earnings
2026-11-09
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -34,013,000 -32,162,000 200,706,000 97,922,000 25,025,000
Jun 2026 0 — -35,099,000 -32,933,000 232,282,000 76,548,000 28,124,000
Mar 2026 0 — -48,008,000 -45,440,000 267,076,000 79,317,000 33,367,000
Dec 2025 0 — -54,934,000 -44,867,000 315,218,000 95,713,000 39,784,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-140,572,000
Investing CF
$160,698,000
Financing CF
$452,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.95
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-633,104,000
Inventory
—
Receivables
—
ST Investments
$93,277,000
EBIT TTM
$-172,054,000
Pretax Income TTM
$-162,058,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -180,887,000 -158,349,000 315,218,000 39,784,000 275,434,000 -132,031,000
Dec 2024 0 -192,950,000 -168,385,000 464,668,000 25,801,000 438,867,000 -135,499,000
Dec 2023 0 -164,162,000 -135,956,000 594,968,000 39,776,000 555,192,000 -85,395,000
Dec 2022 0 -130,650,000 -115,909,000 666,708,000 26,136,000 640,572,000 -120,982,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-165,289,000
OpCashFlow TTM
—
Assets (Latest)
$232,282,000
Forward EPS
$-1.36

Peers — same industry

TickerNameMarket CapLastDaily %
RLMD RELMADA THERAPEUTICS, INC. $321.15M $3.01 —
LRMR Larimar Therapeutics, Inc. $310.61M $2.99 —
INO INOVIO PHARMACEUTICALS, INC. $305.31M $1.63 —
LYEL Lyell Immunopharma, Inc. $336.08M $13.67 —
CTNM Contineum Therapeutics, Inc. $337.62M $9.55 —

News headlines (Yahoo Finance, 1h cache)

Atea Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-10 02:10 · Yahoo
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
2026-11-10 01:00 · Yahoo
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 21:05 · Yahoo
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
2026-11-09 12:00 · Yahoo
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
2026-11-02 21:05 · Yahoo
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-08 11:00 · Yahoo
Atea (AVIR) Q2 2026 Earnings Call Transcript
2026-08-19 21:13 · Yahoo
Atea Pharmaceuticals Q2 Earnings Call Highlights
2026-08-12 22:04 · Yahoo
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
2026-08-05 11:00 · Yahoo
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
2026-07-29 09:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.